SCHEMBL3679328

SCHEMBL3679328

CCCN(CCSc1ccc(OCC(=O)O)c(C)c1)S(=O)(=O)c1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.44
PPARD Q03181 10/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA12 O43570 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
ABCC2 Q92887 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
UGT1A7 Q9HAW7 1/20 0.43
SLC22A11 Q9NSA0 1/20 0.43
CA1 P00915 1/20 0.43
PTPN1 P18031 2/20 0.42
PPARA Q07869 1/20 0.41
APEX1 P27695 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681848 0.93 KEAP1 (0.45) PTGDR2PPARDCA2CA9CA12
SCHEMBL3691500 0.92 PPARD (0.49) PTGDR2PPARDCA2CA9CA12
SCHEMBL3686523 0.91 PTPN1 (0.45) PTGDR2PPARDCA2CA9CA12
SCHEMBL3697015 0.91 PPARD (0.52) PTGDR2PPARDCA2CA9CA12
SCHEMBL3683309 0.91 PPARD (0.45) PTGDR2PPARDCA2CA9CA12
SCHEMBL3689567 0.91 PPARD (0.52) PTGDR2PPARDCA2CA9CA12
SCHEMBL3691579 0.91 PPARD (0.42) PTGDR2PPARDCA2CA9CA12
SCHEMBL3694596 0.90 CA9 (0.46) PTGDR2PPARDCA2CA9CA12
SCHEMBL3692840 0.90 PPARD (0.49) PTGDR2PPARDPTPN1PPARA
SCHEMBL3683314 0.90 PPARD (0.45) PTGDR2PPARDCA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG PTGDR2 328/4885PPARD 1/4885CA2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.